Does resveratrol increase the risk of bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Resveratrol Does Increase Bleeding Risk

Yes, resveratrol can cause bleeding and should be discontinued 2 weeks before surgery due to its antiplatelet effects. 1

Mechanism of Bleeding Risk

Resveratrol increases bleeding risk through multiple pathways:

  • Inhibits platelet aggregation via COX pathway inhibition
  • Blocks cellular calcium channels that are necessary for platelet function
  • Interferes with thromboxane B2 synthesis (similar mechanism to aspirin) 1

The antiplatelet effect is dose-dependent and clinically significant at supplemental doses.

Clinical Evidence and Recommendations

Perioperative Management

The Society for Perioperative Assessment and Quality Improvement (SPAQI) 2021 consensus statement explicitly categorizes resveratrol among supplements that increase bleeding risk 1. The guideline recommends:

  • Hold resveratrol for 2 weeks before surgery due to uncertain drug clearance and metabolism
  • This recommendation places resveratrol in the same category as garlic, ginkgo, ginseng, and vitamin E
  • The 2-week window accounts for complete elimination and restoration of normal platelet function

Drug Interactions

Resveratrol significantly enhances anticoagulant effects of warfarin through two mechanisms 2, 3:

  • Inhibits CYP2C9 (the enzyme that metabolizes S-warfarin, the more potent enantiomer)
  • Inhibits BCRP (breast cancer resistance protein), reducing warfarin excretion
  • This combination increases warfarin exposure and INR, raising bleeding risk

In animal studies, 0.5% dietary resveratrol enhanced warfarin's anticoagulant activity despite increased CYP2C activity, demonstrating the net effect favors bleeding 2.

Important Clinical Caveats

Common pitfall: Patients may not report resveratrol use because it's marketed as a "natural" cardiovascular supplement. Specifically ask about:

  • Red wine extract supplements
  • Anti-aging supplements
  • Cardiovascular health products
  • Grape seed or Japanese knotweed extracts

Risk stratification: The bleeding risk is particularly concerning in patients who:

  • Take anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel)
  • Have underlying coagulopathies
  • Are scheduled for procedures with high bleeding risk
  • Have renal or hepatic impairment (affecting resveratrol metabolism)

Strength of Evidence

The guideline recommendation 1 is based on:

  • Established antiplatelet mechanisms in vitro
  • Documented drug interactions with warfarin in controlled studies 2, 3
  • Consensus expert opinion from anesthesiology and internal medicine specialists
  • Precautionary principle given uncertain pharmacokinetics

While direct clinical bleeding events from resveratrol monotherapy are not extensively documented in humans, the mechanistic evidence and drug interaction data support treating it as a bleeding risk, particularly in the perioperative setting or when combined with other antithrombotic agents.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.